Global Clinical Microbiology Market, By Product (Instruments, Reagents), Indication (Respiratory Diseases, Bloodstream Infections, Gastrointestinal Diseases, Sexually Transmitted Diseases, Urinary Tract Infections, Periodontal Diseases, Other), Application (Pharmaceutical Applications, Food Testing Applications, Clinical Applications, Energy Applications, Chemical and Material Manufacturing Applications, Environmental Applications)– Industry Trends and Forecast to 2029
Market Analysis and Size
Genome sequencing-based assays, characterisation assays, genome sequencing-based assays, and mass spectrometry-based detection are all making significant progress in clinical microbiology. Furthermore, in recent years, laboratory automation and information systems linkage for big data and AI methods have been implemented in the clinical microbiology sector. The ability to detect microorganisms quickly in a clinical microbiology laboratory appears to be critical in determining the best patient management options for fungal, bacterial, and mycobacterial illnesses. Furthermore, clinical microbiology relies on a professional and specialised personnel to process and interpret clinical specimen results.
Data Bridge Market Research analyses that the clinical microbiology market which was USD 3.9 billion in 2021, would rocket up to USD 6.53 billion by 2029, and is expected to undergo a CAGR of 6.65% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Product (Instruments, Reagents), Indication (Respiratory Diseases, Bloodstream Infections, Gastrointestinal Diseases, Sexually Transmitted Diseases, Urinary Tract Infections, Periodontal Diseases, Other), Application (Pharmaceutical Applications, Food Testing Applications, Clinical Applications, Energy Applications, Chemical and Material Manufacturing Applications, Environmental Applications)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
BioMérieux (France), Danaher (US), BD (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), 3M (US), Bio-Rad Laboratories (US), Bruker (US), Hologic Inc. (US), Merck KGaA (Germany), Diagnóstica Longwood SL (Chennai), Agilent Technologies Inc. (U.S), Memmert GmbH + Co.KG (Germany), Hardy Diagnostics (U.S), NEOGEN Corporation (U.S)
Clinical microbiology is an area of medicine that helps detect, prevent, and cure infectious diseases. It focuses on applying several assays to detect the presence of bacterial, viral, fungal, or parasitic agents as well as determine microorganism susceptibility. Typical testing approaches include direct smears and stains, cultures, molecular analysis, serological testing, and antibiotic susceptibility testing. Clinical microbiology is gaining popularity around the world as a result of improved antibiotic delivery and therapeutic effects.
Clinical Microbiology Market Dynamics
- Increased funding and public-private investment
In the forecast period of 2022-2029, the substitution of old empirical approaches in clinical diagnostics to detect infectious pathogens such as virus, fungi, and bacteria is expected to fuel the growth of the clinical microbiology market. Increased funding and public-private investment, on the other hand, will further strengthen numerous opportunities, resulting in the clinical microbiology market's rise over the forecast period.
- Technological advancement is leading to better adaptations of end user products
With the advent of technology, molecular diagnostic tools aid in early detection and effective treatment. These enhanced molecular diagnostic methodologies imply higher sample throughput, faster turnaround times, more specificity, increased accuracy, and reaction multiplicity. NGS, molecular cartridges, real-time PCR, and PCR plus mass spectrometry are examples of sophisticated molecular diagnostic procedures that can analyse several samples in a single input. This characterization and identification of chemicals and pathogens allows for product adaption among major end users such as healthcare practitioners, pharmaceutical and biotechnology companies, and research facilities. This would create an atmosphere of global clinical microbiology market expansion.
- Prioritizing healthcare infrastructure
Governments all over the world, particularly in emerging markets, will provide the clinical biological industry with a varied range of opportunities. The rising ubiquity of diseases like malaria, influenza, tuberculosis, and HIV, as well as several other genetic efficient diseases, has created significant growth potential. Developing-country research and development measures to improve healthcare infrastructure, healthcare spending, and the availability of cost-effective clinical microbiological goods would help to boost market growth characteristics.
One of the major factor driving the market's growth is the rising occurrence of infectious diseases around the world. Furthermore, rising air and water pollution levels are leading to an increase in the number of people developing respiratory ailments, which drives the market. Aside from that, the incorporation of automation in clinical microbiology is boosting market growth since it allows for specimen traceability, decreases incubation delays, and increases laboratory efficiency. Furthermore, the major competitors are concentrating on adopting technology improvements in illness diagnostics, such as the use of machine learning (ML), which aids in the delivery of speedy and accurate results. This, together with the emergence of many molecular diagnostic techniques, is presenting the market with lucrative growth potential.
- Limited or no capitalization in developing countries
Clinical microbiological testing methods are reimbursed very little or not at all in nations like China, India, and others in the Middle East and Africa. The lack of reimbursements inhibits the adaption of clinical microbiological tests and processes when there is a large target patient group.
This clinical microbiology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the clinical microbiology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 impact on Clinical Microbiology Market
The pandemic of COVID-19 has a deep impact on the clinical microbiology sector. Manufacturing and supply chain challenges confront the industry, such as timely delivery of products to end-users and responding to an uneven demand for the sector's products and services. A shortage of skilled laboratory professionals to conduct and study diagnostic tests, decreasing number of operations in most industries, insufficient funding for research and academic institutes, the temporary closure of major academic institutes, a disrupted supply chain, and challenges in providing essential/post-sales services due to lockdowns have all contributed to a decrease in the supply of clinical microbiology products to end-users. One of the most common end-users of clinical microbiology products is research institutes.
Invisible Sentinel (US), a firm that develops, manufactures, and marks molecular diagnostic equipment for the rapid, accurate, and reliable detection of infections and spoilage organisms in food and drinks, was bought by BioMérieux (France) in 2019.
Global Clinical Microbiology Market Scope
The clinical microbiology market is segmented on the basis of product type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Laboratory Instruments
- Microbiology Analyzers
- Respiratory Ailments
- Bloodstream Infections
- Sexually Transmitted Diseases
- Gastrointestinal Diseases
- Urinary Tract Infections
- Periodontal Diseases
- Pharmaceutical Applications
- Food Testing Applications
- Clinical Applications
- Energy Applications
- Chemical and Material Manufacturing Applications
- Environmental Applications
Clinical Microbiology Market Regional Analysis/Insights
The clinical microbiology market is analysed and market size insights and trends are provided by country, product type, application and end-user as referenced above.
The countries covered in the clinical microbiology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the clinical microbiology market due to the ongoing research on infectious disease treatment and grants from government agencies.
Asia-Pacific is expected to florish with the highest growth rate in the forecast period of 2022 to 2029 with respect to rising population that is resulting in high prevalence of diseases such as cholera, typhoid and tuberculosis.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Clinical Microbiology Market Share Analysis
The clinical microbiology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to clinical microbiology market.
Some of the major players operating in the clinical microbiology market are:
- BioMérieux (France)
- Danaher (US)
- BD (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- QIAGEN (Netherlands)
- 3M (US)
- Bio-Rad Laboratories (US)
- Bruker (US)
- Hologic Inc. (US)
- Merck KGaA (Germany)
- Diagnóstica Longwood SL (Chennai)
- Agilent Technologies Inc. (U.S)
- Memmert GmbH + Co.KG (Germany)
- Hardy Diagnostics (U.S)
- NEOGEN Corporation (U.S)